Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News PAVmed Inc PAVMZ


Primary Symbol: PAVM

Healthcare Medical Devices
PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates through three lines of business: Medical Devices, Diagnostics, and Digital Health. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device... see more

Recent & Breaking News (NDAQ:PAVM)

Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test

PR Newswire 6 days ago

Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

PR Newswire 8 days ago

PAVmed Provides Business Update and Third Quarter 2024 Financial Results

PR Newswire 12 days ago

Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication

PR Newswire November 7, 2024

Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers

PR Newswire November 5, 2024

PAVmed to Hold a Business Update Conference Call and Webcast on November 14, 2024

PR Newswire October 31, 2024

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 13, 2024

PR Newswire October 30, 2024

Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test

PR Newswire October 15, 2024

PAVmed Subsidiary, Veris Health, Awarded $1.8 Million NIH Grant to Enhance Cancer Care

PR Newswire October 10, 2024

Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit

PR Newswire October 9, 2024

Lucid Diagnostics to Join Global Medtech Leaders at The MedTech Conference 2024

PR Newswire October 8, 2024

Lucid Diagnostics Holds Inaugural #CheckYourFoodTube Precancer Testing Event for Former NFL Players

PR Newswire October 1, 2024

American Foregut Society's 2024 Annual Meeting to Highlight Lucid Diagnostics' EsoGuard Esophageal Precancer Test

PR Newswire September 24, 2024

PAVmed Announces Efforts to Regain Compliance with Nasdaq Listing Requirements

PR Newswire September 16, 2024

Lucid Diagnostics to Host Symposium on Non-Endoscopic Esophageal Precancer Screening at the 20th International Society for Diseases of the Esophagus (ISDE) World Congress

PR Newswire September 10, 2024

Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health

PR Newswire September 3, 2024

Lucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard® for Early Detection of Esophageal Precancer and Cancer

PR Newswire August 20, 2024

The American Foregut Society Formally Requests Medical Policy Coverage of EsoGuard® to Enhance Early Detection of Esophageal Cancer

PR Newswire August 13, 2024

PAVmed Provides Business Update and Second Quarter 2024 Financial Results

PR Newswire August 13, 2024

Lucid Diagnostics Provides Business Update and Second Quarter 2024 Financial Results

PR Newswire August 12, 2024